Subscribe

0

Biologics License Application

Data Protection Technology For SMEs

Eisai Presents New Data from Lecanemab Phase 2B Study

For Early Alzheimer's Disease in Late-Breakers and Pipeline Updates at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

By SMEStreet Edit Desk
Nov 04, 2021 08:05 IST 2 Min read